Extended Data Fig. 2: PFS by C4D15 ctDNA MRD status in patients with DLBCL and no CR at C4D15. | Nature Cancer

Extended Data Fig. 2: PFS by C4D15 ctDNA MRD status in patients with DLBCL and no CR at C4D15.

From: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial

Extended Data Fig. 2

N = 35 ctDNA-evaluable patients (n = 8 with cleared MRD at C4D15; n = 27 with detected MRD at C4D15). Data are presented as Kaplan–Meier curves, with tick marks indicating patients with censored data. The HR for PFS in patients with MRD cleared versus MRD detected was calculated by univariate Cox regression. C4D15, cycle 4 day 15; CI, confidence interval; CR, complete response; ctDNA, circulating tumor DNA; DLBCL, diffuse large B-cell lymphoma; HR, hazard ratio; MRD, minimal residual disease; PFS, progression-free survival.

Source data

Back to article page